Subcutaneous pharmaceutical composition containing a mutant of human hyaluronidase PH20 and a drug

摘要

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition containing (a) a drug and (b) a human PH20 mutant. SOLUTION: The human PH20 variant contained in the pharmaceutical composition according to the present invention has an alpha helix 8 sequence (S347 to C381), and an alpha helix 7 and an alpha helix in a wild-type human PH20 having the amino acid sequence of SEQ ID NO: 1. It comprises an amino acid substitution at one or more sites selected from the linking sites (A333 to R346) with 8, and is characterized in that the amino acids located at the N-terminal or C-terminal portion are selectively cleaved. Further, the pharmaceutical composition according to the present invention may further contain a pharmaceutically acceptable additive, particularly a stabilizer. The pharmaceutical composition according to the present invention can maximize the therapeutic effect of the concomitant drug by the effect of the human PH20 mutant. [Selection diagram] FIG. 20